Barclays’s AnaptysBio ANAB Stock Holding History

Barclays’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-30,000	Closed	-$676K	–	4843
2024 Q1	$676K	Buy	+30,000	New	+$710K	﹤0.01%	3402
2019 Q1	–	Sell	-8,800	Closed	-$561K	–	6984
2018 Q4	$561K	Sell	8,800 -60,300	-87%	-$4.48M	﹤0.01%	3711
2018 Q3	$6.89M	Buy	69,100 +42,300	+158%	+$3.51M	﹤0.01%	1520
2018 Q2	$1.9M	Buy	26,800 +16,000	+148%	+$1.34M	﹤0.01%	2629
2018 Q1	$1.12M	Buy	+10,800	New	+$1.22M	﹤0.01%	3064

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barclays's ANAB Position: Q1 2026 in Review

Barclays reduced its AnaptysBio (ANAB) stake by 88% in Q1 2026, selling an estimated $2.81M and leaving 7,440 shares worth $413K. The position accounts for ﹤0.01% of the portfolio, ranked #3295.

Barclays first reported a position in ANAB in Q1 2017 and has held it in 37 quarters since. The position peaked at $12.4M in Q3 2018. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

Barclays held 7,440 shares of AnaptysBio worth $413K as of Q1 2026.
Barclays sold 52,214 AnaptysBio shares in Q1 2026, an estimated $2.81M.
AnaptysBio made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3295 holding.
Barclays first reported a position in AnaptysBio in Q1 2017 and has held it in 37 quarters since.
Barclays's AnaptysBio position peaked at $12.4M in Q3 2018.
207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.